Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAZAI: Gazyvaro + Radiotherapy in Early Stage Nodal Follicular Lymphoma
NCT03341520Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Apr 2018
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in follicular lymphoma (FL), sponsored by Heidelberg University. Primary endpoint: Rate of metabolic complete remission at 18 weeks. Started Apr 2018; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03341520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341520.